Patents by Inventor Erik Verner

Erik Verner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10870652
    Abstract: Provided herein, inter alia, are compounds and methods for modulating Bruton's Tyrosine Kinase.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: December 22, 2020
    Assignee: CORVUS PHARMACEUTICALS, INC.
    Inventors: Ryan Hudson, Anne-Marie Beausoleil, Richard A. Miller, Erik Verner
  • Publication number: 20200190092
    Abstract: The present disclosure provides compounds of Formula (IA) and/or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK, and are potentially useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and/or pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: December 9, 2019
    Publication date: June 18, 2020
    Applicant: PRINCIPIA BIOPHARMA INC.
    Inventors: Tim OWENS, Erik VERNER
  • Publication number: 20200079793
    Abstract: Disclosed herein, inter alia, are compositions and methods for modulating Adenosine Receptors.
    Type: Application
    Filed: August 30, 2019
    Publication date: March 12, 2020
    Inventors: Zhihong Li, Lubov Konstantinovna Filonova, Erik Verner
  • Patent number: 10538517
    Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: January 21, 2020
    Assignee: Principia Biopharma, Inc.
    Inventors: Kenneth Albert Brameld, Erik Verner
  • Patent number: 10533013
    Abstract: The present disclosure provides compounds of Formula (IA), such as, e.g., (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enenitrile having the chemical structure ?and/or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK inhibitors, and are potentially useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and/or pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: January 14, 2020
    Assignee: Principia Biopharma Inc.
    Inventors: Tim Owens, Erik Verner
  • Publication number: 20190233418
    Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: April 12, 2019
    Publication date: August 1, 2019
    Inventors: Erik VERNER, Kenneth Albert BRAMELD
  • Patent number: 10294223
    Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: May 21, 2019
    Assignee: PRINCIPIA BIOPHARMA, INC.
    Inventors: Erik Verner, Kenneth Albert Brameld
  • Publication number: 20190106423
    Abstract: Provided herein, inter alia, are compounds and methods for modulating Bruton's Tyrosine Kinase.
    Type: Application
    Filed: March 10, 2017
    Publication date: April 11, 2019
    Inventors: Ryan HUDSON, Anne-Marie BEAUSOLEIL, Richard A. MILLER, Erik VERNER
  • Publication number: 20180327413
    Abstract: The present disclosure provides compounds of Formula (IA) and/or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK, and are potentially useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and/or pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: May 11, 2018
    Publication date: November 15, 2018
    Applicant: PRINCIPIA BIOPHARMA INC.
    Inventors: Tim OWENS, Erik VERNER
  • Patent number: 9994576
    Abstract: The present disclosure provides compounds of Formula (II) as disclosed herein, and/or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK inhibitors, and are potentially useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and/or pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: June 12, 2018
    Assignee: PRINCIPIA BIOPHARMA INC.
    Inventors: Tim Owens, Erik Verner
  • Publication number: 20180155340
    Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: May 18, 2016
    Publication date: June 7, 2018
    Inventors: Kenneth Albert BRAMELD, Erik VERNER
  • Publication number: 20180065960
    Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: November 8, 2017
    Publication date: March 8, 2018
    Inventors: Erik VERNER, Kenneth Albert BRAMELD
  • Patent number: 9815834
    Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: November 14, 2017
    Assignee: PRINCIPIA BIOPHARMA, INC.
    Inventors: Erik Verner, Kenneth Albert Brameld
  • Patent number: 9630963
    Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: April 25, 2017
    Assignee: PRINCIPIA BIOPHARMA, INC.
    Inventors: Kenneth Albert Brameld, Erik Verner
  • Patent number: 9567334
    Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: February 14, 2017
    Assignee: Principia Biopharma, Inc.
    Inventors: Erik Verner, Kenneth Albert Brameld
  • Patent number: 9556182
    Abstract: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: January 31, 2017
    Assignee: Pharmacylics LLC
    Inventors: Lee Honigberg, Erik Verner, Joseph J. Buggy, David Loury, Wei Chen
  • Publication number: 20160251358
    Abstract: The present disclosure provides compounds of Formula (IA) and/or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK, and are potentially useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and/or pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: January 15, 2016
    Publication date: September 1, 2016
    Applicant: PRINCIPIA BIOPHARMA INC.
    Inventors: Tim OWENS, Erik VERNER
  • Publication number: 20160229849
    Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: February 4, 2015
    Publication date: August 11, 2016
    Inventors: Erik VERNER, Kenneth Albert BRAMELD
  • Patent number: 9409911
    Abstract: Disclosed herein are compounds, including compounds having the structure of Formula (A), (B), (C), and (D), as described in further detail herein, that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: August 9, 2016
    Assignee: Pharmacyclics LLC
    Inventors: Lee Honigberg, Erik Verner, Zhengying Pan
  • Publication number: 20160200725
    Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: March 22, 2016
    Publication date: July 14, 2016
    Inventors: Erik VERNER, Kenneth Albert BRAMELD